Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. - Wikidata - wikimedia - TriplyDB

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

http://www.wikidata.org/entity/Q37514596

about

Safety issues associated with using medication to treat overactive bladder.[Overactive bladder-which treatment when?]Quo Vadis Botulinum Toxin: Normative Constraints and Quality of Life for Patients With Idiopathic OAB?

P2860

Q40058585-54DBC4F2-5DA9-4C5E-8779-872FC5386E99 Q50085927-73B55F38-DF5B-4BFD-A0C7-C7647E33F4E8 Q58554566-0759E9EA-39EE-4148-A17B-747711E913AC

P2860

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

http://www.wikidata.org/entity/Q37514596

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@en

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@nl

type

label

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@en

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@nl

prefLabel

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@en

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.

@nl

P1433

Q37514596-F0C4B7CF-C90D-4288-A22C-A049E5597BD1

P1476

Q37514596-5E6DDEBF-0B32-41FD-B503-780358ADCC4A

P2093

Q37514596-A1F36D97-F3E1-44A3-978C-BBA749A13350

P2860

Q37514596-02372D9F-B865-49CB-A4AE-0353E98B1C7B

Q37514596-0D9DCD28-9401-403D-BAF9-5131EDDCB22F

Q37514596-112F550F-0A22-413A-81F4-5E6E4D3586B6

Q37514596-1BD5415A-0DFE-41E7-A173-87394A4DCAC1

Q37514596-1EE7A1CF-DFF5-499D-BD18-722C05DE0164

Q37514596-24BC57A6-0434-41A3-B292-D85D64F80EB8

Q37514596-34132082-3197-4A6A-9FC2-B4015EEA5150

Q37514596-42CB6DE0-D3F2-486F-9023-C1344F6EB845

Q37514596-4B640080-56D2-4DB9-9E7A-ACF9CFB3AA47

Q37514596-6EE23F51-EB89-49BA-96B1-C25FD00B3F24

P304

Q37514596-D3483EF3-4E59-4E61-9BD7-A7835699583E

P31

Q37514596-40A03C37-C878-4B8E-A5A7-9EA28A1A174B

P356

Q37514596-8C27FE15-972F-4BD8-8D38-9E05C22D68BA

P433

Q37514596-E2F3A095-09FD-436E-970D-A3FD53349D2F

P478

Q37514596-687308C0-765C-4ECC-BF44-7331D6530133

P50

Q37514596-9D3D18CE-D6D8-4600-8554-5ADEB710398D

P577

Q37514596-2E2B75FA-A66E-441F-8F16-F6B0A71E7166

P698

Q37514596-3612DF9A-B3E0-48C3-A4B3-3EECD6DB3CEA

P932

Q37514596-D0CADE59-D766-4AF7-8FD2-35BAE8DE8567

P356

1756287216672180

P1433

Therapeutic advances in urology

P1476

Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder

@en

P2093

David Eldred-Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

Botulinum toxin type A products are not interchangeable: a review of the evidence.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

Clinical comparability of marketed formulations of botulinum toxin.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

EAU guidelines on urinary incontinence.

Immunogenicity of botulinum toxins.

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

P304

3-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287216672180

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28042308

http://www.w3.org/2001/XMLSchema#string

P932

5167072

http://www.w3.org/2001/XMLSchema#string